Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 6/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159943 | 0.95 | CHKA (0.53) | ALDH1A1LMNACHKAKDM4ECA2 | |
| SCHEMBL18580511 | 0.90 | ALDH1A1 (0.48) | ALDH1A1LMNAMC4RCHKANPC1 | |
| SCHEMBL18580284 | 0.88 | SIGMAR1 (0.42) | HRH3 | |
| SCHEMBL20635708 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNAMC4RCHKAHDAC6 | |
| SCHEMBL13277275 | 0.86 | SMN1; SMN2 (0.49) | ALDH1A1LMNAKDM4EMAPTNPC1 | |
| SCHEMBL2509532 | 0.85 | MC4R (0.44) | ALDH1A1LMNAMC4RCHKAHDAC6 | |
| Hydrochloric Acid SCHEMBL3619140 | 0.85 | SMN1; SMN2 (0.48) | KDM4ENPC1TP53RAB9AHPGD | |
| SCHEMBL18580590 | 0.82 | HRH3 (0.35) | HDAC6HRH3 | |
| SCHEMBL28440571 | 0.82 | LMNA (0.53) | ALDH1A1LMNAMC4RCHKAHDAC6 | |
| SCHEMBL1428193 | 0.80 | GAA (0.42) | ALDH1A1LMNACHKAKDM4ENCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-20140275006-A1 | AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-18 | — | — | US | disclosed |
| EP-2772482-A1 | AZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243315-A1 | PYRROLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2763988-A1 | PYRROLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | The University of North Carolina at Chapel Hill (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| WO-2013052417-A1 | PYRROLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2121687-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | ALDH1A1 3880/4885LMNA 1281/4885MC4R 94/4885 |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LMNA 3611/4885MC4R 509/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ALDH1A1 3864/4885LMNA 1144/4885MC4R 180/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LMNA 3611/4885MC4R 509/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | ALDH1A1 3880/4885LMNA 1281/4885MC4R 94/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | ALDH1A1 3864/4885LMNA 1144/4885MC4R 180/4885 |
| US-20140243315-A1 | PYRROLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | MERTK, BCR, RET | ALDH1A1 2238/4885LMNA 4458/4885MC4R 2828/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | ALDH1A1 3115/4885LMNA 3611/4885MC4R 509/4885 |
| US-20140275006-A1 | AZOLE DERIVATIVE | AVPR1B, AVPR1A, AVPR2 | ALDH1A1 1469/4885LMNA 4563/4885MC4R 5/4885 |
| US-20100093718-A1 | Compounds | FGFR1, FGFR2, PDGFRB | ALDH1A1 379/4885LMNA 3496/4885MC4R 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.